Skip to main
ALLK
ALLK logo

Allakos Inc (ALLK) Stock Forecast & Price Target

Allakos Inc (ALLK) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 30%
Hold 40%
Sell 10%
Strong Sell 0%

Bulls say

Allakos Inc. is advancing its clinical-stage pipeline with AK006, a therapeutic antibody aimed at selectively targeting Siglec-6 found on mast cells, which may significantly reduce mast cell activation tied to various diseases. The innovative mechanism of action of AK006 positions the company favorably within the competitive landscape of immunomodulatory therapies, potentially leading to substantial market opportunities as clinical trials progress. Furthermore, Allakos's strong financial position, indicated by its recent funding rounds, provides the necessary capital to support ongoing research and development, enhancing investor confidence in the company's future growth prospects.

Bears say

Allakos Inc's financial outlook appears negative due to its clinical-stage status and lack of commercialized products, which typically results in significant operating losses and a reliance on external funding. The company's lead program, AK006, while targeting a potentially valuable therapeutic area, faces the inherent risks associated with the development of new treatments, including potential delays or failure in clinical trials. Additionally, the substantial cash burn rate and limited cash reserves raise concerns about the company's ability to sustain operations without securing additional financing in the near future.

Allakos Inc (ALLK) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 30% recommend Buy, 40% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allakos Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allakos Inc (ALLK) Forecast

Analysts have given Allakos Inc (ALLK) a Buy based on their latest research and market trends.

According to 10 analysts, Allakos Inc (ALLK) has a Buy consensus rating as of Aug 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allakos Inc (ALLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.